Skip to main content

GENCOR INDUSTRIES INC

For the period ended Mar 31, 2025. Filed Jul 25, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2025 · Filed Jul 25, 2025

GENC$17.00+1.7%Stored close · as of Nov 6, 2026

What changed in Risk Factors?

Read the current filing

Previous report: 10-Q

Period ended 2024-06-30; filed 2024-08-09.

0001193125-24-197832

Item 1A. Risk Factors

Current report: 10-Q

Period ended 2025-03-31; filed 2025-07-25.

0001193125-25-164840

Item 1A. Risk FactorsOther Information

The baseline is this issuer’s latest earlier reporting period of the same form that was filed before the current report. A previous 10-Q is a different quarter, not a year-over-year comparison. Amendments are excluded.

Compared 11 previous paragraphs and 20 current paragraphs.

7 unchanged; 1 reworded; 12 added; 3 removed; 0 previous and 0 current paragraphs rearranged.

Tables are not compared: 0 previous and 0 current tables excluded. Dates, whitespace, punctuation and numbering changes are ignored; changes to financial figures remain significant.

A changed paragraph is not evidence that risk increased or decreased. An unchanged paragraph does not establish that risk stayed the same.

Added paragraphs (12)

Current report

for the year ended September 30, 2024.

Current report

Plan Adoptions, Modifications and Terminations

Current report

During the quarter ended March 31, 2025, none of the Company’s directors or officers adopted, modified or terminated a Rule

Current report

trading arrangement or a

Current report

non-Rule

Current report

trading arrangement (each as defined in Item 408 of Regulation

Current report

under the Exchange Act).
Removed paragraphs (3)

Previous report

for the year ended September 30, 2023, other than the addition of the following risk factor:

Previous report

Changes in our tax rates or exposure to additional tax liabilities could adversely affect our earnings and financial condition

Previous report

Beginning in 2022, the Tax Cuts and Jobs Act of 2017 eliminated the option of expensing all research and development expenditures in the current year, instead requiring amortization over five years pursuant to IRC Section 174. In the future, Congress may consider legislation that would eliminate the capitalization and amortization requirement. There is no assurance that the requirement will be deferred, repealed or otherwise modified. The requirement is effective for the Company’s fiscal year 2023, beginning October 1, 2022. The Company will continue to make additional estimated federal tax payments based on the current Section 174 tax law. The impact of Section 174 on the Company’s cash from operations depends primarily on the amount of research and development expenditures incurred and whether the IRS issues guidance on the provision which differs from the Company’s current interpretation.
Reworded paragraphs (1)

Previous wording

During the nine months ended June 30, 2024, there have been no material changes from the risk factors previously disclosed under Part I, Item 1A, “Risk Factors” in our Annual Report on Form

Current wording

During the six months ended March 31, 2025, there have been no material changes from the risk factors previously disclosed under Part I, Item 1A, “Risk Factors” in our Annual Report on Form